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Loss of Bcl2 in invasive breast cancer is associated
with high rates of cell death, but also with increased
proliferative activity
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Summary Bcl-2 has been demonstrated to inhibit apoptosis in breast cancer cells in vitro, and the ratio between Bcl-2 and its proapoptotic
homologue Bax seems to be an important determinant of cellular sensitivity to induction of apoptosis. However, little information is available
on the relationship between Bcl-2 and the rate of apoptotic and necrotic cell death in breast tumours. From a series of 441 premenopausal,
lymphnode-negative breast cancer patients, a subset of 49 tumours was selected in which immunostaining for the 26-kDa isoform of Bcl-2
was either absent (n = 23) or very high (n = 26). High expression of Bcl-2 was found to be strongly associated with low rates of apoptotic
(P < 0.001) and necrotic cell death (P < 0.001). The mean value of the apoptotic index was 2.69% ± 1.40% in Bcl-2-negative tumours and
0.68% ± 1.00% in Bcl-2-positive tumours. Expression of the proapoptotic protein Bax correlated neither with Bcl-2 nor with the frequency of
apoptotic cells. Immunostaining for the antiapoptotic Bcl-2 homologue Bcl-XL correlated with Bcl-2 expression (P < 0.001) but not with
apoptosis. High proliferation rate and high tumour grade (Bloom-Richardson) were strongly associated with absence of Bcl-2 expression
(P < 0.001). p53 accumulation was associated with absence of Bcl-2 expression and increased apoptotic activity. Loss of Bcl-2 expression
was strongly correlated with increased apoptotic and necrotic cell death, high proliferation rate and high tumour grade, supporting a model in
which Bcl-2 not only mediates cell death, but also cell division in breast cancer tissue, and in which regulation of cell division and cell death
are tightly linked.
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Cellular factors affecting sensitivity to the induction of apoptosis
may modulate resistance of tumour cells to cytotoxic drugs and
irradiation (Kerr et al, 1994; Reed, 1994). Members of the bcl-2
gene family (Korsmeyer, 1995) play acrucial role in theregulation
of apoptosis and can be divided into members promoting cell
survival (for example bcl-2, bcl-XL and mcl-1) and members
promoting cell death (for example bax, bak and bcl-Xs). Bcl-2
overexpression has been shown to protect against cell death
induced by many different stimuli, including chemotherapeutic
drugs; for example in acute myeloid leukaemia, Bcl-2 expression
has been reported to be strongly associated with resistance to
chemotherapy (Campos et al, 1993). In breast cancer, high expres-
sion ofBcl-2 was found to occur predominantly in well-differenti-
ated tumours and to be strongly correlated with favourable
prognosis (Bhargava et al, 1994; Joensuu et al, 1994; Leek et al,
1994; Silvestrini et al, 1994; van Slooten et al, 1996). Evaluating
the value of Bcl-2 as a predictive factor for the responsiveness of
breast tumours to a combination of 5-fluorouracil (5-FU), doxo-
rubicin and cyclophosphamide (FAC) we found that Bcl-2 protein
expression assessed by immunohistochemistry, did not predict
response to adjuvant chemotherapy (van Slooten et al, 1996). This
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lack ofpredictive value of Bcl-2 expression, which has also been
found for 5-FU based chemotherapy in colorectal adenocarci-
nomas (Schneider et al, 1997), is not in line with most in vitro
experiments, which clearly suggest an increased resistance to
chemotherapy in tumour cell lines overexpressing Bcl-2.
Assuming that increased resistance to induction of apoptosis
leads to increased resistance to chemotherapy, this could imply
that in breast tumours Bcl-2 has little impact on the sensitivity to
induction of apoptosis. However, it may also be possible that the
efficacy ofBcl-2 to inhibit apoptosis is determined in large part by
interactions with other proteins, including other Bcl-2 family
members, by post-translational modification, such as phosphory-
lation (Blagosklonny et al, 1996; Guan et al, 1996) or mutations.
If immunohistochemically detectable Bcl-2 protein is by itself
capable of attenuating the rate of cell death in breast cancer cells,
one may expect a strong correlation between Bcl-2 staining and
the proportion of apoptotic cells and/or necrotic areas in breast
cancer tissue. We wanted to test this in our series oftumours from
441 node-negative, premenopausal breast cancer patients, previ-
ously analysed for Bcl-2 immunostaining (van Slooten et al,
1996). However, apoptosis is a difficult variable to adequately
quantitate in tissue sections. With the use of terminal transferase
(TdT)-mediated dUTP nick end-labelling (TUNEL) it is possible
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to visualize single cells or areas in a tissue containing fragmented
DNA, but because of the fragmentation of the apoptotic nuclei
quantitation remains difficult. Therefore, to unequivocally detect
an effect ofBcl-2 expression on apoptotic activity, we determined
the apoptotic index and the amount of necrosis in a preselected
series of49 breast cancers that eithercompletely lacked or showed
strong staining for Bcl-2 protein.
The results presented here show that in invasive breast cancer,
loss of Bcl-2 expression is closely correlated with increased
apoptotic and necrotic cell death, high proliferation rate and high
tumour grade. Our findings support a model in which Bcl-2 not
only mediates cell death but also cell division in breast cancer
tissue and in which regulation of cell division and cell death are
tightly linked.
MATERIALS AND METHODS
From a series of 441 node-negative, premenopausal breast cancer
patients, previously analysed for Bcl-2 immunostaining (van
Slooten et al, 1996), a subset of 49 tumours (including 41 ductal
carcinomas) was selected, in which Bcl-2 was either absent
(n = 23) or strongly stained (n = 26). Apart from Bcl-2, various
prognostic factors (including p53, ER, Ki-67, mitotic index) have
been analysed previously (Clahsen et al, 1997).
Immunohistochemical analysis
The expression of Bcl-2, p53, oestrogen receptor (ER) and Ki-67
was determined immunohistochemically on paraffin sections
using a microwave antigen retrieval method, the monoclonal
antibodies clone 124 (Bcl-2, Boehringer Mannheim, Mannheim,
Germany), Do-7 (p53, Dako, Glostrup, Denmark), iD5 (ER,
Dako), mPRI (PgR Transbio, Paris, France), 3B5 (c-ErbB-2 (van
de Vijver et al, 1988)), MIB-1 (Ki-67 antigen, Immunotech,
Marseilles, France) and the polyclonal antibodies 3666E (Bax,
PharMingen, San Diego, CA, USA), I-19 (Bax, Santa Cruz, CA,
USA) and S-18 (Bcl-X, Santa Cruz).
Briefly, sections were deparaffinized in xylene, endogenous
peroxidase was blocked in methanol/hydrogen peroxide 0.03% for
20 min and sections were rehydrated. Next, sections were heated
in 10 mm citrate buffer pH 6.0, 100°C, for 10 min in a microwave
oven and cooled down for 2 h. After washing in double-distilled
water followed by phosphate-buffered saline (PBS), sections were
incubated overnight with the primary antibody (clone 124, 1:100;
Do-7, 1:100; lD5, 1:200; mPRI, 1:80; 3B5, 1:20000; MIB-1,
1:200; 3666E, 1:1000; 1-19, 1:400). After thorough washing in
PBS, sections were incubated with biotinylated secondary anti-
bodies (DAKO) followed by StreptABComplex (Dako). Staining
was visualized using diaminobenzidine (Sigma, St Louis, MO,
USA). Depending on the antibody, sections were scored either
semiquantitatively (Bcl-2, p53, ER) or quantitatively (Ki-67) as
described previously (Clahsen et al, 1997; van Slooten et al, 1996).
The mitotic index was determined by counting the number of
mitosis per ten high-power fields in H&E sections. Staining for
microvessels was done using the monoclonal antibody clone
IC/70A (Dako) against CD31, as previously described (Clahsen et
al, 1997). Microvessel density (MVD) was determined by
counting the most vascular area at low magnification (25x).
Vessels were then counted on three 250x (0.384 mm2) fields, of
which the highest count was used for statistical analysis.
Detection of apoptotic cells
Apoptotic cells were visualized using terminal transferase (TdT)-
mediated dUTP nick end-labelling ofDNA strand breaks according
to a protocol described by Gavrieli et al (1992), using the enzyme
TdT (Boehringer Mannheim) and biotinylated dUTP (Boehringer
Mannheim). Optimal results were obtained by preheating tissue
sections in 10 mm citrate buffer (pH 6.0, 70°C, 20min), followed by
treatment with 20 gml-' proteinase K(BoehringerMannheim) for60
min at 37°C. Afterthorough washing in TBS (pH 7.4), sections were
incubated with StreptABComplex (Dako) and the tailing reaction
was visualized using diaminobenzidine (Sigma). Sections were
counterstained with ethyl green. Using aZeiss Axioscop microscope
(Carl Zeiss, Oberkochen, Germany) with a checkerboard grid in the
ocular, tissue sections were analysed at a magnification of 640x;
within the grid frame all tumour cells were counted. Within each
section a variable number ofrandomly distributed areas was evalu-
ated until at least 1000 tumour cells had been counted. Positively
stained cells that also displayed an apoptotic morphology (i.e. cell
shrinkage and nuclear condensation/fragmentation) were scored and
expressed as a percentage of tumour cells or apoptotic index (Al).
Necrotic areas were excluded from the analysis. The analysis was
performed withoutpriorknowledge ofBcl-2 expression.
The amount ofnecrosis in each section was scored semiquanti-
tatively by two observers (H-JvS and MJvdV), using four cate-
gories: none, low (< 25% per field at a magnification of 100x),
intermediate (25-50% per field at a magnification of 100x) and
high (> 50% per field at a 100x magnification).
Statistical methods
Differences between distributions of variables among patient
groups were tested for using Fischer's exact test. Correlations
between continuous variables were expressed using the Wilcoxon
coefficient. Median, interquartile range and minimum and
maximum values were used to analyse the effects and interactions
of several factors at once. The median (0.77%) was used as a cut-
offvalue for apoptotic index, whereas for necrosis the cut-offwas
none vs low, intermediate and high. Bax and Bcl-XL expression
were scored using the scoring system previously described for
Bcl-2 (van Slooten et al, 1996). Bax-negative tumours and
Bcl-X -negative tumours were defined as those tumours with a
staining score of 3 and 2 respectively. The median value ofMVD
was used as cut-offvalue (109 mm-2). The cut-off values used for
the other prognostic factors were identical to the values used in
previous analyses. Statistical analyses were performed using the
StatExact (Cytel Software Corporation, Cambridge, MA, USA)
and SPSS-software (SPSS, Chicago, IL, USA).
RESULTS
The majority oftumours in this preselected series either showed a
very low or a very high rate of apoptosis. Table 1 shows the asso-
ciations between Bcl-2 expression, apoptotic activity and prolifer-
ative activity. As shown, Bcl-2 expression was correlated with a
low apoptotic index (Al) (P < 0.001) and low proliferative activity
as determined by mitosis count and immunostaining for the Ki-67
antigen (P <0.001). The median value ofthe Al was 2.67% in Bcl-
2-negative tumours and 0.39 in Bcl-2-positive tumours. Figure 1
shows representative examples of Bcl-2 and TUNEL staining in
Bcl-2-positive and Bcl-2-negative tumours. Table 2 summarizes
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Table 1. Expression of Bcl-2 is associated with low apoptotic index (Al), low
mitototic counts and low Ki-67 positivity
Median Al Range P-value
Bcl-2 negative 2.67 0.01-5.24
Bcl-2 positive 0.39 0.00-4.69 <0.001a
Median mitosis count
Bcl-2 negative 21.00 2.00-36.00
Bcl-2 positive 2.00 1.00-33.00 <0.001a
Median Ki-67 positivity
Bcl-2 negative 34.50 2.00-65.00
Bcl-2 positive 15.00 1.50-48.00 <Q.OOla
a Wilcoxon rank test.
the association between Bcl-2 expression, cell death, other Bcl-2
family members and various established prognostic factors. When
the Al was dichotomized with the median (0.77%) as cut-off
value, 87.5% of tumours with AIs lower than 0.77% stained posi-
tive for Bcl-2, whereas in only 20.0% of tumours with AIs higher
than 0.77% was Bcl-2 expression present. Expression ofthe apop-
tosis-promoting protein Bax (as determined by two different poly-
clonal antibodies, which gave similar results) did not correlate
A
W
R
with Bcl-2 (P = 0.751), whereas expression of the antiapoptotic
protein Bcl-XL was associated with expression of Bcl-2
(P < 0.001). However, neither Bax nor Bcl-XL expression signifi-
cantly affected the mean AIs in Bcl-2-positive and Bcl-2-negative
tumours respectively.
As shown, we also semiquantitatively assessed the amount of
necrosis. Ofthe tumours without necrotic areas 68.0% were Bcl-2-
positive, whereas only 32.0% of the tumours with necrotic areas
were Bcl-2-positive (P = 0.003). In line with their lack of correla-
tion with the Al, neither Bax nor Bcl-XL expression correlated
with necrosis.
Although this series of breast cancers had been preselected for
lack of Bcl-2 expression and high Bcl-2 expression, tumour cell
proliferation and tumour grade were also highly associated with
apoptosis. Table 3 shows a cross-tabulation ofapoptotic index and
the number of mitosis, Ki-67 positivity, tumour grade and p53
status. Of the 26 tumours with 0-9 mitosis, five (19.2%) had high
rates of apoptosis, whereas in 12 (92.3%) of the 13 tumours with
counts greater than or equal to 20 the rate of apoptosis was high.
Apoptotic and mitotic activity showed a good correlation
(Wilcoxon rank test, P < 0.001). Of the 19 tumours with less than
20% Ki-67-positive cells (a measure for tumour growth fraction)
two (10.5%) displayed a high rate of apoptosis, whereas 22
C
D
Figure 1 Representative examples of TUNEL in breast carcinomas lacking Bcl-2 vs tumours expressing high levels of Bcl-2. (A) Ductal carcinoma with
strong Bcl-2 expression. (B) Invasive breast carcinoma lacking Bcl-2 expression. Positively stained infiltrating lymphocytes. (C) TUNEL of tumour shown in A.
(D) TUNEL of tumour shown in B
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Table 2 Association of Bcl-2 expression with apoptosis and various prognostic factors
Variables Bcl-2 expression Totals P-value
Negative Positive
Apoptotic index
<0.77%
.0.77%
Necrosis
None
Low/medium/high
Bax-status
Negative
Positive
Bcl-X-status
Negative
Positive
ER-status
Negative
Positive
PgR-status
Negative
Positive
Number of mitosis
0- 9
10-19
.20
Ki-67 positivity
<20%
>20%
p53-status
Negative
Positive
c-ErbB-2
Negative
Positive
Bloom-Richardson
Grade
Grade II
Grade IlIl
MVD
<109 mm2
.109 mm2
a Wilcoxon rank test
(73.3%) of the 30 tumours with more than 20% Ki-67-positive
cells displayed high rates ofapoptosis (P < 0.001). Ofthe 13 grade
I tumours (Bloom-Richardson), one (7.7%) had a high rate of
apoptosis, whereas 18 (90%) of the 20 grade III tumours had a
high rate of apoptosis (Wilcoxon rank test, P < 0.001). Of the 34
p53-negative tumours, 14 (41.2%) displayed a high rate of
apoptosis, whereas 11 (73.3%) of the 15 p53-positive tumours
displayed a high rate of apoptosis. The mean value of the AI was
1.31 ± 1.46 in p53-negative tumours and 2.34 ± 1.60 in p53-
positive tumours (P = 0.046).
Figure 2 shows box plots depicting the median, interquartile
range, as well as the minimum and maximum values ofAIs in Bcl-
2-negative and Bcl-2-positive tumours with either low and high
mitotic activity (Figure 2A) and Ki-67 positivity (Figure 2B)
respectively. These graphs show that the median apoptotic index
is consistently higher in rapidly proliferating tumours and is
especially high in those rapidly proliferating tumours that do not
express Bcl-2. MVD was correlated neither with Bcl-2 expression
(Table 2) nor with apoptotic or necrotic activity (data not shown).
DISCUSSION
Our data confirm that in early invasive breast cancer the absence
of immunohistochemically detectable Bcl-2 correlates not only
with the presence of apoptotic cells (scattered within tumour
tissue), but also with the presence of large areas of ischaemic
necrosis. This would suggest that Bcl-2 affects not only the
threshold for induction of apoptosis in well-oxygenized parts of
tumours but also sensitivity to necrosis in ischaemic parts. Of
interest, it has been reported that in vitro hypoxia may induce both
British Journal ofCancer (1998) 77(5), 789-796
3 (12.5)
20 (80.0)
5 (22.7)
17 (68.0)
14 (53.8)
7 (43.8)
16 (59.3)
5 (25.0)
19 (95.0)
4 (13.8)
18 (90.0)
5 (17.2)
6 (23.1)
5 (50.0)
12 (92.3)
2 (16.5)
21 (70.0)
11 (32.4)
12 (80.0)
16 (40.0)
7 (77.8)
1 (7.7)
6 (37.5)
16 (80.0)
9 (42.9)
8 (36.4)
21 (87.5)
5 (20.0)
17 (77.3)
8 (32.0)
12 (46.2)
9 (56.3)
11 (40.7)
15 (75.0)
1 (5.0)
25 (86.2)
2 (10.0)
24 (82.8)
20 (76.9)
5 (50.0)
1 (7.7)
17 (89.5)
9 (30.0)
23 (67.6)
3 (20.0)
24 (60.0)
2 (22.2)
12 (92.3)
10 (62.5)
4 (20.0)
12 (57.1)
14 (63.6)
24 (49.0)
25 (51.0)
22 (46.8)
25 (53.2)
26 (61.9)
16 (38.1)
27 (57.4)
20 (42.6)
20 (40.8)
29 (59.2)
20 (40.8)
29 (59.2)
26 (53.1)
10 (20.4)
13 (26.5)
19 (38.8)
30 (61.2)
34 (69.4)
15 (30.6)
40 (81.6)
9 (18.4)
13 (26.5)
16 (32.7)
20 (40.8)
21 (48.8)
22 (51.2)
<0.001
0.003
0.751
<0.001
<0.001
<0.001
<0.001a
<0.001
0.004
0.064
<0.001a
0.663
0 CancerResearch Campaign 1998Cell death andBcl-2expression in breast cancer 793
Table 3 Cross-tabulation of apoptotic index and mitotic counts
Apoptotic index
< 0.77% >0.77% Total P-value
Number of mitosis
0-9 21 (80.8) 5 (19.2) 26 (53.1)
10-19 2 (20.0) 8 (80.0) 10 (20.4)
>20 1 (7.7) 12 (92.3) 13 (26.5) <0.001a
Ki-67 positivity
<20% 16 (84.2) 3 (15.8) 19 (38.8)
.20% 8 (26.7) 22 (73.3) 30 (61.2) <0.001
Bloom-Richardson
Grade 12 (92.3) 1 (7.7) 13 (26.5)
Grade II 11(68.8) 5 (31.3) 16 (32.7)
Grade III 1 (5.0) 19 (95.0) 20 (40.8) <0.001a
p53-status
Negative 20 (58.8) 14 (41.2) 34 (69.4)
Positive 4 (26.7) 11(73.3) 15 (30.6) =0.046
aWilcoxon rank test.
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Figure 2 Box plots depicting the median, interquartile range, as well as the
minimum and maximum values of Als in Bcl-2-negative and Bcl-2-positive
tumours with either low and high mitotic activity (A) and Ki-67 positivity (B).
The median is depicted by the horizontal bars, the interquartile range by the
boxes and the minimum and maximum values by the vertical bars. Outliers
are marked by open circles and extreme values by asterisks. (A) Mitosis
count: *, 0-9; O, >9. (B) Ki-67 positivity: *, <20%; O, >20%
necrosis and apoptosis, and that both types of cell death can be
partially prevented by the expression ofBcl-2 or Bcl-X, as well as
by inhibitors ofenzymes known to be involved in the execution of
apoptosis (caspases). This suggests that apoptosis and ischaemic
necrosis may share certain biochemical pathways (Shimizu et al,
1995a; 1996).
It has been demonstrated that hypoxia can result in the selection
of tumour cells with increased resistance to apoptosis (Graeber et
al, 1996). Therefore, as one would expect a strong selection pres-
sure for reduced susceptibility to apoptosis during tumorigenesis,
the finding of relatively high rates of apoptotic cell death in
high-grade carcinomas seems counter-intuitive. There are several
aspects to this paradox: although referred to as 'rate ofapoptosis',
staining of apoptotic cells and bodies gives little information on
the actual rapidity of cell loss by this process, i.e. the duration of
the execution phase and the removal and further degradation of
apoptotic debris upon phagocytosis. Furthermore, it has been
demonstrated that in a model ofpancreatic tumorigenesis the tran-
sition frompremalignant to malignantdisease is characterized by a
decrease in apoptotic but not proliferative activity (Naik et al,
1996). Thus, even although in some tumours the observed
frequency of apoptosis was high, it is not unthinkable that this
frequency would have been even higher in the preinvasive
stadium. In addition, as high-grade tumours are oftencharacterized
by marked genetic heterogeneity (for example with respect to
chromosome numbers) many tumour cells may die as a result of
their genetic instability.
Although in vitro experiments clearly showed that Bcl-2 over-
expression confers resistance to apoptosis induced by cytotoxic
treatment, Bcl-2 did not predict response to chemotherapy in
women with node-negative early breast cancer (van Slooten et al,
1996). However, the strong inverse correlation between Bcl-2
and cell death suggests that Bcl-2 is an important regulator of
apoptosis in breast cancer.
The efficacy of Bcl-2 to inhibit cell death depends in part on its
binding to other proteins, including other members of the Bcl-2
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family: for example binding of Bcl-2 to the proapoptotic protein
Bax has been reported to be essential for proper function of Bcl-2
(Yin et al, 1995) and therefore the ratio of these two proteins is
believed tobe an importantdeterminant ofcellularsensitivity to the
induction of apoptosis. In breast cancer cells in vitro, increased
Bcl-2/Bax ratios reduced the cytotoxicity of taxol (Huang et al,
1997). Furthermore, loss of Bax expression in vivo was associated
with worse prognosis and apositive correlation was found between
Bcl-2 and Bax expression (Krajewski et al, 1995). Hypersensitivity
of testicular tumours to drug-induced apoptosis was reported to be
associated with a low Bcl-2/Bax ratio (Chresta et al, 1996).
In the present study, Bax staining (as determined with the use of
two different antibodies) did not correlate with Bcl-2 and co-
expression of Bax was not associated with changes in the rate of
apoptosis. Expression of the antiapoptotic Bcl-2 family member
Bcl-X correlated with expression ofBcl-2, but expression of Bcl-
X in Bcl-2-negative tumours did not seem to protect against
apoptosis, suggesting that in this series suppression of apoptosis
depends on Bcl-2 rather than Bcl-X. However, it is important to
note that only the two extremes of Bcl-2 expression were studied.
Although this approach minimized the impact of the imprecision
inherent in TUNEL staining, as a consequence the applicability of
these findings to tumours with intermediate levels of Bcl-2 will
need to be confirmed. We cannot exclude the possibility that in
tumours expressing low to intermediate levels of Bcl-2 coexpres-
sion of other Bcl-2 family members has a significant effect on the
rate ofapoptosis.
Although identified as a proto-oncogene in B-cell lymphomas,
Bcl-2 overexpression does not seem to be sufficient to transform
normal mammary epithelial cells (Lu et al, 1995). In vitro and in
vivo experiments suggest that: (a) Bcl-2 expression is controlled
by oestrogen (Sabourin et al, 1994; Teixeira et al, 1995; Wang and
Phang, 1995) and (b) it has been proposed that, by increasing cell
survival of breast epithelial cells, Bcl-2 may facilitate differentia-
tion in the mammary gland (Lu et al, 1995). The present data
strongly confirm an inverserelationship between Bcl-2 expression
and poor differentiation in breast cancer (Bhargava et al, 1994;
Joensuu et al, 1994; Leek et al, 1994; Silvestrini et al, 1994;
Lipponen et al, 1995; van Slooten et al, 1996). This relationship
between Bcl-2 and differentiationgrade has notonly beenreported
in invasive breast cancer but also in ductal carcinoma in situ
(DCIS) (Siziopikou et al, 1996). In aprevious study, we noted that
the majority of Bcl-2-negative invasive tumours were accompa-
nied by Bcl-2-negative DCIS (H-J. van Slooten, unpublished
data). This finding suggests that these tumours either originated
from Bcl-2-negative cells or had already lost Bcl-2 expression
before invasive tumour growth.
A strong inverse correlation between Bcl-2 and proliferative
activity has been reported to exist in breast cancer, as well as other
tumour types, and the data presented here are in line with these
findings. Typically, tumours that lack Bcl-2 expression are ofhigh
grade and havehigh rates ofbothproliferation and cell death, indi-
cating the existence ofrapid cell turnover. Although one has to be
cautious with the interpretation of these data because this breast
tumour series has been preselected, the correlations found are
highly significant, making it unlikely that they do not reflect an
underlying biological mechanism. In fact, we recently confirmed
our present findings in a series of 206 breast cancers (H-J van
Slooten, manuscript in preparation) and similar relationships
between apoptosis, proliferation and high tumour grade were
reported for other tumour types (Lipponen and Aaltomaa, 1994;
Aihara et al, 1995; Du et al, 1996; Isacson et al, 1996; Koshida et
al, 1996; Shoji et al, 1996). For instance, in gastric cancer, Bcl-2
expression was positively correlated with a low Al and MI,
whereas Bax expression seemed to be correlated with an increased
AI and MI. In line with our findings, no correlation was found
between Bcl-2/Bax ratios and either AI or MI (Koshida et al,
1996). In DCIS, apoptotic activity has been reported to be corre-
lated with high grade (Bodis et al, 1996), indicating a correlation
with proliferative activity.
It is becoming increasingly clear that certain genes needed for
proliferation and transformation play a double role; for example
overexpression of c-myc increases the rate of proliferation but at
the same time dramatically increases the rate ofapoptosis (Evan et
al, 1992). Deregulation of a number of important components in
the growth-regulating pathway seem to result not only in the
inability to control cell growth, but also apoptosis andpost-mitotic
differentiation (Field et al, 1996; Kranenburg et al, 1996; Wang et
al, 1997). The strong correlation of cell division and cell death in
breast cancers suggests that, similar to c-myc overexpression in
vitro, deregulated expression of genes important for proliferation
leads to conflicting signals in many cells in vivo, which in turn
may induce apoptosis.
Increasing evidence indicates that under certain conditions the
induction of apoptosis depends on cell cycle progression and the
activity of proteins involved in cell cycle regulation: for example
cyclins and cyclin-dependent kinases and their inhibitors
(Donaldson et al, 1994; Shi et al, 1994; Shimizu et al, 1995b;
Pandey and Wang, 1995; Wang et al, 1995; Yao et al, 1996a,b;
Zornig and Evan, 1996). Thus, if cell cycle regulatory genes are
linked to theregulation ofapoptosis, genes importantforapoptosis
may in turn be directly linked to the growth-regulating pathway.
Interestingly, it has been reported that Bcl-2 overexpression
causes a retardation of mammalian cell proliferation (Pietenpol et
al, 1994). Bomer et al found that whereas Bcl-2 negative cells
would die from any point in the cell cycle, Bcl-2 overexpressing
cells tended to accumulate in GIG1. Co-expression of Bax
reverted both the death protection and inhibition ofcell prolifera-
tion, whereas aBcl-2 mutantprotein defective in cell death protec-
tion did not affect cell proliferation (Borner, 1996). Similarly,
Bcl-2 and its homologues Bcl-X and adenovirus ElB19kD were
reported to inhibitcell cycle entry ofquiescentNIH3T3 fibroblasts
and human colon carcinoma cells (Pietenpol et al, 1994; O'Reilly
et al, 1996; Theodorakis et al, 1996). Overexpression of Bax has
been reported to have the opposite effect, increasing the number of
cycling thymocytes and accelerating entry into S-phase ofcycling
T cells (Brady et al, 1996). These data suggest that Bcl-2 and its
homologues contribute to cell survival by diminishing the rate of
cell proliferation and possibly allowing cells to undergo terminal
differentiation. It is tempting to hypothesize that the preferential
expression of Bcl-2 in well-differentiated, slowly proliferating
epithelial tumours reflects this connection between Bcl-2 and both
cell cycle retardation and differentiation.
Missense mutations in the p53 gene often lead to increased
protein stability, resulting in a cellular accumulation ofthe mutant
protein, which can be detected using immunohistochemistry
(Sjogren et al, 1996). In breast cancer, a negative correlation is
known to exist between Bcl-2 expression and p53 protein accu-
mulation (Silvestrini et al, 1996). p53 plays an important role in
maintaining genomic stability, regulation of the cell cycle and
induction of apoptosis (Ko and Prives, 1996). In Rb-deficient
mice, the loss of p53 function caused resistance to apoptosis
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(Morgenbesser et al., 1994), and the loss ofboth Rb andp53 func-
tion has a cooperative effect on tumorigenesis in the mouse
(Williams et al., 1994). In this study, p53 accumulation seemed to
be associated with increased rather then decreased apoptotic
activity, suggesting that many of the apoptotic events observed
are p53-independent. At present, we are investigating the relation-
ship between p53 mutations, confirmed by DNA mutation
analysis, and cell death in a larger series ofbreast cancers.
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